Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab from the First Episode of Idiopathic Nephrotic Syndrome
2018-003437-15Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab in nephrosis and Idiopathic nephrotic syndrome (INS) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2019; status: active.
02
Drugs
rituximab
03
Conditions
nephrosisIdiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2018-003437-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003437-15.